Cutting HCP Data Costs 70% Without Losing Engagement

The question worth answering

HCP audience data in oncology is expensive, and the premium is usually defended on precision. That defense is rarely tested, because the alternative is assumed to be worse targeting. But data fees are not free targeting: every dollar of data cost is a dollar not spent on impressions, and in a specialty category with a small prescriber universe, working media is the constraint that actually binds.

The question this campaign put to the test was narrow and answerable. If you swap in a lower-cost data source at the same total budget, do you keep the engagement quality you were paying the premium for?

What the data showed

Engaged user rate, defined here as engaged sessions divided by total sessions, rose 55% month over month to 27% blended across the campaign. The four Swoop segments averaged 29%, ahead of both the blended campaign rate and the 20% category benchmark. Click-through held at 0.31% against a 0.07% benchmark, so the engagement gain did not come at the expense of front-end response.

The spread matters as much as the average. A single breakout carrying the result would suggest one lucky segment; four of four above benchmark, with a 24-point range between best and worst, suggests the data source itself is doing work while still leaving obvious optimization headroom. Breakout A at 46% is more than double the benchmark and is the natural place to concentrate the next flight.

Where the money went

The mechanic here is unglamorous and worth stating clearly, because it is the part that transfers to any campaign. Data fees sit inside the CPM before a single impression delivers. Cutting them 70% did not make the targeting smarter by itself; it made roughly $6,800 available to buy qualified HCP reach at the same total budget. In a specialty category where the prescriber universe is small and reach is the binding constraint, that reallocation is the whole play.

What the campaign then had to prove is that the cheaper data did not quietly cost quality. On engaged user rate and CTR, in this month, it did not.

What I would take to the next plan

Price audience data as a share of working media, not as a line item. A data fee that consumes a meaningful slice of a specialty budget has to earn that slice against the reach it displaces. The question is never whether the premium data is better, it is whether it is better by more than the impressions it costs you.

Separate what a change caused from what happened around it. The cost saving and the engagement lift arrived in the same month, and only one of them is cleanly attributable. Writing the readout the other way, with the full 55% credited to the data swap, would have been the more impressive slide and the less useful one when the next flight is planned.

Use segment spread to find the next move. Four segments above benchmark with a 24-point range is a map. Breakout A gets more budget, Breakout D gets a structural look before it gets more money, and the read is designed to make that decision obvious rather than to declare victory.

Push engagement wins toward an Rx read. Engaged user rate is a legitimate leading indicator for HCP display, and it is not a prescription. The next version of this test carries the same segments into an outcomes study so the efficiency argument can be made in the currency that matters. That architecture is covered in the Pharma Programmatic Measurement Framework, and the targeting context in Mastering HCP Targeting Best Practices.